Search results
Promising trial data for Moderna's skin cancer vaccine sends stock rising
Quartz· 53 minutes agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
US FDA approves Moderna’s RSV vaccine, its second marketed product
WHTC 1450 Holland· 3 days agoBy Patrick Wingrove (Reuters) - The U.S. Food and Drug Administration has approved Moderna's...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 6 hours agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 7 hours agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 8 hours ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
RBC Capital lifts Moderna shares target, highlights RSV vaccine approval By Investing.com
Investing.com· 9 hours agoThe revision follows the approval of Moderna's Respiratory Syncytial Virus (RSV) vaccine by...
FDA approves Moderna’s RSV vaccine mRESVIA
Pharmaceutical Technology via Yahoo Finance· 12 hours agoIn 2023, Moderna agreed to establish an mRNA manufacturing facility in Kenya. The new advanced facility will have the capacity to produce up to 500...
Moderna Investors Just Got Some Bullish News | The Motley Fool
The Motley Fool· 11 hours agoModerna (MRNA 3.91%) jumped into the limelight when it started developing a coronavirus vaccine...
Is Moderna Stock a Buy Now That It's a 2-Product Company? | The Motley Fool
The Motley Fool· 10 hours agoThe shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 5 hours agoThe vaccine, a critical component of Moderna’s pipeline, has bolstered investor confidence following...
